ArticleJournal of translational medicine2026
The GFPT2/O-GlcNAcylation/c-Myc axis promotes bladder cancer progression.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundGlucose metabolic reprogramming is a hallmark of bladder cancer. However, the exact relationship between glucose metabolism and the onset and progression of bladder cancer remains poorly understood.
methodsWe integrated a metabolic gene interaction perturbation network with machine learning algorithms to identify GFPT2 as a metabolic prognostic gene in bladder cancer. External validation was performed through survival analysis using clinical cohort data. GFPT2 expression levels was assessed by RT‒qPCR, Western blotting, and immunohistochemistry. To further explore the protumorigenic role of GFPT2, cell function experiments and animal studies were conducted. Coimmunoprecipitation and immunofluorescence techniques were used to investigate the interactions between the key downstream molecules, c-Myc and OGT, and GFPT2.
resultsGFPT2 expression was higher in bladder cancer tissues than in normal tissues, and high GFPT2 expression was closely associated with poor prognosis in bladder cancer patients. GFPT2 overexpression promoted the proliferation and migration of bladder cancer cells. Mechanistic studies revealed that GFPT2 regulated the O-GlcNAcylation of c-Myc, inhibited its ubiquitination-mediated degradation, and thereby enhanced c-Myc stability, which promoted the proliferation and migration of bladder cancer cells.
conclusionThis study reveals a novel mechanism involving the GFPT2/O-GlcNAcylation/c-Myc signalling axis in the malignant progression of bladder cancer. These findings provide a theoretical basis for potential new therapeutic strategies targeting bladder cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.